About US
Contact us
-
Bausch Health inks $200M ‘stalking horse’ deal for bankrupt Trulance maker SynergyCould a still-recovering company buying a distressed one create a better business? Bausch Health apparently thinks so when it comes to Synergy Pharma, as it's agreed to pay $200 million for the now-ba2018/12/10
-
Boehringer Ingelheim chops 295 jobs in France but vows $380M in animal health investmentsWhen German pharma Boehringer Ingelheim completed a $12.5 billion asset swap with France’s Sanofi in 2016, BI traded its consumer health business for Sanofi’s veterinary unit andagreedto make the Fren2018/12/10
-
Roche’s Tecentriq gets FDA priority review to treat small cell lung cancerThe US Food and Drug Administration (FDA) has granted priority review for Roche’s Tecentriq (atezolizumab) in combination with chemotherapy for treating extensive-stage small cell lung cancer (ES – SC2018/12/7
-
Novartis, aiming to protect blockbuster sales, advances Xolair follow-up to phase 3With blockbuster Xolair aging, Novartis is looking to usher in a successor to protect its sales. And it got one step closer this week. The Swiss drugmaker willadvancecandidate ligelizumab—a treatment2018/12/7
-
Takeda receives shareholders’ approval to acquire ShireTakeda Pharmaceutical has secured shareholder approval for the issuance of its shares necessary to implement the proposed $62bn acquisition of Shire. The Japanese pharmaceutical company received at l2018/12/6
-
Boehringer and Domain Therapeutics form CNS drug discovery allianceBoehringer Ingelheim has signed a drug discovery collaboration and licensing agreement with Domain Therapeutics for the development of new drugs to treat central nervous system (CNS) diseases. The mu2018/12/6
-
UCB to invest £1bn in the UK Life Sciences Sector DealBelgian biopharmaceutical company UCB has agreed to invest approximately £1bn ($1.27bn) as part of a collaboration between the UK government and life sciences industry intended to support health2018/12/5
-
FDA agrees accelerated approval pathway for GBT’s voxelotorThe US Food and Drug Administration (FDA) has granted San Francisco-based Global Blood Therapeutics (GBT)’s sickle cell disease (SCD) therapy voxelotor an accelerated approval under the subpart H path2018/12/5
-
GSK wraps up promised Horlicks sell-off in £3.1B deal with UnileverAfter weighing options and offers for its Horlicks drinks brand in India for several months, GlaxoSmithKline signed off on a £3.1 billion sale to Unilever. The cash will help GSK cover the cos2018/12/4
-
GlaxoSmithKline, looking to pump up in new favorite oncology, buys Tesaro for $5.1BTesaro has been busy looking to sell itself. And now it's found itself a buyer in GlaxoSmithKline, which recently rejigged to refocus on cancer. GSK is shelling out $5.1 billion to acquire the oncolo2018/12/4